SCHEMBL1132369

SCHEMBL1132369

CN[C@@H](CO)CNC(C)(C)c1ccccc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
MAPT P10636 1/20 0.36
GAA P10253 2/20 0.35
CASR P41180 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
ADRB2 P07550 2/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
ADRB1 P08588 1/20 0.33
ATM Q13315 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132372 1.00 AGTR1 (0.37) AGTR1LMNACYP1A2MAPTGAA
SCHEMBL12608429 0.86 MEN1 (0.36) AGTR1LMNACYP1A2MAPTGAA
SCHEMBL1132931 0.82 AGTR1 (0.38) AGTR1LMNACYP1A2MAPTGAA
SCHEMBL1133190 0.81 MAPT (0.36) MAPTGAACASRMEN1KMT2A
SCHEMBL1132330 0.81 AGTR1 (0.35) AGTR1LMNACYP1A2MAPTGAA
SCHEMBL1132334 0.81 AGTR1 (0.35) AGTR1LMNACYP1A2MAPTGAA
SCHEMBL1132332 0.80 ALDH1A1 (0.38) AGTR1LMNACYP1A2GAACASR
SCHEMBL27679895 0.79 CA1 (0.39) MAPTGAACASRMEN1KMT2A
SCHEMBL12608591 0.77 ALDH1A1 (0.36) AGTR1LMNACYP1A2MAPTGAA
SCHEMBL1986850 0.77 KMT2A (0.38) MAPTGAAMEN1KMT2AMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 AGTR1 4520/4885LMNA 1555/4885CYP1A2 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.